Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2019/09/021158
CTRI/2019/09/021158
Active, not recruiting
Phase 4

A Real-World, Prospective, Observational Study to Evaluatethe Safety and Effectiveness of Rivaroxaban (Xarelto®) forPrevention of Stroke and Systemic Embolism in IndianPatients with Non-valvular Atrial Fibrillation (NVAF) - XARI

Bayer Zydus Pharma Private Limited0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: I489- Unspecified atrial fibrillation and atrial flutter

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: I489- Unspecified atrial fibrillation and atrial flutter
Sponsor
Bayer Zydus Pharma Private Limited
Status
Active, not recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patient should be an adult female or male, \>\=18 years of age;
  • •Patient should be diagnosed with NVAF and initiated with rivaroxaban treatment for
  • •prevention of stroke or systemic embolism per investigatorâ??s routine treatment practice;
  • •Patient should not have received rivaroxaban in the past;
  • •Patient/patientâ??s legally acceptable representative should be willing to provide written
  • •informed consent.

Exclusion Criteria

  • •1\. Patient has contraindications to receive rivaroxaban therapy according to local prescribing
  • •information;
  • •2\. Patient is receiving anticoagulant therapy for indication other than NVAF and that needs to
  • •be continued as per discretion of treating physician;
  • •3\. Patient is participating in an investigational program with interventions outside of routine
  • •clinical practice.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
An observational study to assess the usefulness of Eberconazole cream (Ebernet®) in patients with tinea (fungal) infectio
CTRI/2019/05/019449Dr Reddys Laboratories Ltd120
Recruiting
Not Applicable
Observational study to compare the reliability and inter-observer variability of three imaging techniques (optical coherence tomography, intravascular ultrasound and angiography) used for stenting in a hospital set-up in India.
CTRI/2019/12/022539Apex Heart Institute
Completed
Not Applicable
Study on Medical Device.Health Condition 1: I779- Disorder of arteries and arterioles, unspecified
CTRI/2021/03/032112The Madras Medical Mission Hospital90
Recruiting
Not Applicable
A change of End tidal Carbon dioxide(EtCO2) during Endoscopic Retrograde Cholangiopancreatography(ERCP) with Carbon dioxide insufflation under general anesthesia with controlled ventilatioEndoscopic Retrograde Cholangiopancreatography (ERCP) with Carbon dioxide (CO2) insufflation in patient ASA physical status 1-3 under general anesthesia with controlled ventilationEndoscopic Retrograde Cholangiopancreatography (ERCP) with Carbon dioxide (CO2) insufflationEnd tidal Carbon dioxide (EtCO2)
TCTR20210824003Department of Anesthesiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University125
Recruiting
Phase 4
Study the effectiveness of Hydroxyzine hydrochloride in Patients with Persistent ItchingHealth Condition 1: null- Chronic Pruritus
CTRI/2017/06/008847Dr Reddys Laboratories Ltd400